인간 피브리노겐 : 시장 점유율과 순위, 전체 매출 및 수요 예측(2025-2031년)

The global market for Human Fibrinogen was estimated to be worth US$ 1259 million in 2024 and is forecast to a readjusted size of US$ 2562 million by 2031 with a CAGR of 10.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Human Fibrinogen cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Human Fibrinogen is a high-purity plasma protein preparation derived from human plasma or produced through recombinant technology, with fibrinogen as its main component. It plays a crucial role in blood clotting, as fibrinogen is converted into fibrin by thrombin to form a blood clot and stop bleeding. Fibrinogen concentrate is primarily used to treat congenital or acquired fibrinogen deficiencies, manage bleeding during surgery or trauma, and address other conditions requiring rapid fibrinogen supplementation.

The market for fibrinogen concentrate is primarily driven by the increasing prevalence of bleeding disorders and surgical procedures that require rapid hemostasis, as well as growing awareness and adoption of targeted blood management therapies. Advances in plasma fractionation and recombinant technologies, along with rising demand for safer, pathogen-reduced, and high-purity blood products, are also fueling market growth. Additionally, an aging population, higher incidence of trauma and cardiovascular surgeries, and expansion of healthcare infrastructure in emerging regions contribute to the increasing demand for fibrinogen concentrate.

Global Human Fibrinogen key players include CSL Behring, LFB Group, Shanghai RAAS Blood Products, Jiangxi Boya Bio-Pharmaceutical, GREEN CROSS, etc. Global top five manufacturers hold a share about 90%. Asia-Pacific is the largest consumption market, with a share about 60%, followed by Americas and Europe, total have a share over 30 percent. In terms of product, Human Fibrinogen Concentrate is the largest segment, with a share over 99%. And in terms of application, the largest application is Surgical Procedures.

This report aims to provide a comprehensive presentation of the global market for Human Fibrinogen, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Human Fibrinogen by region & country, by Type, and by Application.

The Human Fibrinogen market size, estimations, and forecasts are provided in terms of sales volume (Kg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Fibrinogen.

Market Segmentation

By Company

• CSL Behring
• LFB Group
• Shanghai RAAS Blood Products
• China Resources Boya Bio-pharmaceutical
• Hualan Biological Engineering
• Harbin Pacific Biopharmaceutical
• China Meheco Group
• Octapharma

Segment by Type

• Human Fibrinogen Concentrate
• Animal Fibrinogen Concentrate

Segment by Application

• Congenital Fibrinogen Deficiency
• Surgical Procedures
• Others

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Human Fibrinogen manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Human Fibrinogen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Human Fibrinogen in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Human Fibrinogen Product Introduction
• 1.2 Global Human Fibrinogen Market Size Forecast
  • 1.2.1 Global Human Fibrinogen Sales Value (2020-2031)
  • 1.2.2 Global Human Fibrinogen Sales Volume (2020-2031)
  • 1.2.3 Global Human Fibrinogen Sales Price (2020-2031)
• 1.3 Human Fibrinogen Market Trends & Drivers
  • 1.3.1 Human Fibrinogen Industry Trends
  • 1.3.2 Human Fibrinogen Market Drivers & Opportunity
  • 1.3.3 Human Fibrinogen Market Challenges
  • 1.3.4 Human Fibrinogen Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Human Fibrinogen Players Revenue Ranking (2024)
• 2.2 Global Human Fibrinogen Revenue by Company (2020-2025)
• 2.3 Global Human Fibrinogen Players Sales Volume Ranking (2024)
• 2.4 Global Human Fibrinogen Sales Volume by Company Players (2020-2025)
• 2.5 Global Human Fibrinogen Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Human Fibrinogen Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Human Fibrinogen Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Human Fibrinogen
• 2.9 Human Fibrinogen Market Competitive Analysis
  • 2.9.1 Human Fibrinogen Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Human Fibrinogen Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Fibrinogen as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Human Fibrinogen Concentrate
  • 3.1.2 Animal Fibrinogen Concentrate
• 3.2 Global Human Fibrinogen Sales Value by Type
  • 3.2.1 Global Human Fibrinogen Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Human Fibrinogen Sales Value, by Type (2020-2031)
  • 3.2.3 Global Human Fibrinogen Sales Value, by Type (%) (2020-2031)
• 3.3 Global Human Fibrinogen Sales Volume by Type
  • 3.3.1 Global Human Fibrinogen Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Human Fibrinogen Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Human Fibrinogen Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Human Fibrinogen Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Congenital Fibrinogen Deficiency
  • 4.1.2 Surgical Procedures
  • 4.1.3 Others
• 4.2 Global Human Fibrinogen Sales Value by Application
  • 4.2.1 Global Human Fibrinogen Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Human Fibrinogen Sales Value, by Application (2020-2031)
  • 4.2.3 Global Human Fibrinogen Sales Value, by Application (%) (2020-2031)
• 4.3 Global Human Fibrinogen Sales Volume by Application
  • 4.3.1 Global Human Fibrinogen Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Human Fibrinogen Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Human Fibrinogen Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Human Fibrinogen Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Human Fibrinogen Sales Value by Region
  • 5.1.1 Global Human Fibrinogen Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Human Fibrinogen Sales Value by Region (2020-2025)
  • 5.1.3 Global Human Fibrinogen Sales Value by Region (2026-2031)
  • 5.1.4 Global Human Fibrinogen Sales Value by Region (%), (2020-2031)
• 5.2 Global Human Fibrinogen Sales Volume by Region
  • 5.2.1 Global Human Fibrinogen Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Human Fibrinogen Sales Volume by Region (2020-2025)
  • 5.2.3 Global Human Fibrinogen Sales Volume by Region (2026-2031)
  • 5.2.4 Global Human Fibrinogen Sales Volume by Region (%), (2020-2031)
• 5.3 Global Human Fibrinogen Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Human Fibrinogen Sales Value, 2020-2031
  • 5.4.2 North America Human Fibrinogen Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Human Fibrinogen Sales Value, 2020-2031
  • 5.5.2 Europe Human Fibrinogen Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Human Fibrinogen Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Human Fibrinogen Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Human Fibrinogen Sales Value, 2020-2031
  • 5.7.2 South America Human Fibrinogen Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Human Fibrinogen Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Human Fibrinogen Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Human Fibrinogen Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Human Fibrinogen Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Human Fibrinogen Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Human Fibrinogen Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Human Fibrinogen Sales Value, 2020-2031
  • 6.3.2 United States Human Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Human Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Human Fibrinogen Sales Value, 2020-2031
  • 6.4.2 Europe Human Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Human Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Human Fibrinogen Sales Value, 2020-2031
  • 6.5.2 China Human Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Human Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Human Fibrinogen Sales Value, 2020-2031
  • 6.6.2 Japan Human Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Human Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Human Fibrinogen Sales Value, 2020-2031
  • 6.7.2 South Korea Human Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Human Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Human Fibrinogen Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Human Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Human Fibrinogen Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Human Fibrinogen Sales Value, 2020-2031
  • 6.9.2 India Human Fibrinogen Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Human Fibrinogen Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 CSL Behring
  • 7.1.1 CSL Behring Company Information
  • 7.1.2 CSL Behring Introduction and Business Overview
  • 7.1.3 CSL Behring Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 CSL Behring Human Fibrinogen Product Offerings
  • 7.1.5 CSL Behring Recent Development
• 7.2 LFB Group
  • 7.2.1 LFB Group Company Information
  • 7.2.2 LFB Group Introduction and Business Overview
  • 7.2.3 LFB Group Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 LFB Group Human Fibrinogen Product Offerings
  • 7.2.5 LFB Group Recent Development
• 7.3 Shanghai RAAS Blood Products
  • 7.3.1 Shanghai RAAS Blood Products Company Information
  • 7.3.2 Shanghai RAAS Blood Products Introduction and Business Overview
  • 7.3.3 Shanghai RAAS Blood Products Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Shanghai RAAS Blood Products Human Fibrinogen Product Offerings
  • 7.3.5 Shanghai RAAS Blood Products Recent Development
• 7.4 China Resources Boya Bio-pharmaceutical
  • 7.4.1 China Resources Boya Bio-pharmaceutical Company Information
  • 7.4.2 China Resources Boya Bio-pharmaceutical Introduction and Business Overview
  • 7.4.3 China Resources Boya Bio-pharmaceutical Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 China Resources Boya Bio-pharmaceutical Human Fibrinogen Product Offerings
  • 7.4.5 China Resources Boya Bio-pharmaceutical Recent Development
• 7.5 Hualan Biological Engineering
  • 7.5.1 Hualan Biological Engineering Company Information
  • 7.5.2 Hualan Biological Engineering Introduction and Business Overview
  • 7.5.3 Hualan Biological Engineering Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Hualan Biological Engineering Human Fibrinogen Product Offerings
  • 7.5.5 Hualan Biological Engineering Recent Development
• 7.6 Harbin Pacific Biopharmaceutical
  • 7.6.1 Harbin Pacific Biopharmaceutical Company Information
  • 7.6.2 Harbin Pacific Biopharmaceutical Introduction and Business Overview
  • 7.6.3 Harbin Pacific Biopharmaceutical Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Harbin Pacific Biopharmaceutical Human Fibrinogen Product Offerings
  • 7.6.5 Harbin Pacific Biopharmaceutical Recent Development
• 7.7 China Meheco Group
  • 7.7.1 China Meheco Group Company Information
  • 7.7.2 China Meheco Group Introduction and Business Overview
  • 7.7.3 China Meheco Group Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 China Meheco Group Human Fibrinogen Product Offerings
  • 7.7.5 China Meheco Group Recent Development
• 7.8 Octapharma
  • 7.8.1 Octapharma Company Information
  • 7.8.2 Octapharma Introduction and Business Overview
  • 7.8.3 Octapharma Human Fibrinogen Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Octapharma Human Fibrinogen Product Offerings
  • 7.8.5 Octapharma Recent Development

8 Industry Chain Analysis

• 8.1 Human Fibrinogen Industrial Chain
• 8.2 Human Fibrinogen Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Human Fibrinogen Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Human Fibrinogen Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer